ABC News: How AI is Accelerating Drug Discovery
In an ABC News feature, Dotmatics VP Phil Mounteney explains how the company's AI-powered Luma platform accelerates drug discovery by transforming data into actionable insights, streamlining early-stage research, enhancing collaboration, and shortening preclinical timelines amid growing demand for connected, AI-ready data in life sciences.
In a recent ABC News feature, Dotmatics VP of Science and Technology, Phil Mounteney, discusses the transformative role of artificial intelligence in drug development. The article explores how Dotmatics is helping scientific organizations move faster and smarter—turning data into decisions with the power of AI.
From streamlining early-stage research to enhancing collaboration and speeding up preclinical timelines, the Luma platform is changing the way life sciences companies innovate. In the wake of the pandemic and with the rise of mRNA and other advanced modalities, the need for connected, AI-ready data has never been greater.
Read the full article to learn how Dotmatics is shaping the future of R&D.
Related
3 Customer Trends We’re Watching in 2025
In 2025, life science teams are prioritizing three key trends—Lab-in-a-Loop platforms that integrate instruments, data, workflows, and models to boost R&D efficiency; true multimodal discovery enabled by flexible informatics supporting diverse data types without fragmented tools; and Composite AI leveraging layered, governed, and traceable data across disciplines—all aimed at delivering tangible scientific innovation while addressing resource constraints and stringent AI governance requirements.
Maximize Your Data Impact
The article discusses how R&D leaders can maximize the impact of their data by adopting AI/ML technologies, establishing robust data infrastructures, and leveraging automation and external partnerships, as highlighted by insights from Dotmatics' collaboration with LINUS and their State of Science survey revealing scientists' strategic shifts toward automation and partnerships amid scientific and economic challenges.
AI’s Quiet Revolution is Accelerating Drug Discovery, Education and More
The Fast Company article discusses how AI is quietly revolutionizing industries like drug discovery and education by enabling faster, more efficient solutions that address global challenges, with Dotmatics offering personalized demos of their Luma platform to showcase AI capabilities in scientific research.
Addressing Inefficient R&D Workflows
The blog discusses how legacy, fragmented R&D systems hinder innovation in complex, multi-domain scientific research by creating silos and inefficiencies, and presents Dotmatics’ unifying platform as a comprehensive solution that integrates diverse tools, data, and teams to enable smarter collaboration, governed data use, and AI-driven automation for faster, more rigorous innovation.
Data Evolution in Pharma: The Spread of Multimodal
The pharmaceutical industry is shifting from single-mode to multimodal drug discovery, incorporating diverse therapeutic modalities like biologics, gene therapies, and small molecules, but this evolution presents significant challenges in integrating heterogeneous R&D data and technologies, necessitating advanced, compatible platforms to enable efficient collaboration and leverage AI-driven insights for faster, cost-effective drug development.
From Foundational to Aspirational: Dotmatics CEO on the Three Phases of R&D Digital Transformation
Dotmatics CEO outlines the accelerating digital transformation in life sciences R&D driven by exploding data volumes, emphasizing the shift towards AI and machine learning despite unique industry challenges such as lack of standardized interoperability and a fragmented ecosystem, which complicate progress toward a predictive, generative AI-enabled future in drug discovery.